All In Biotech

Drug Trial Radar · NCT04996199

Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial

Comparative Efficacy of Carbamazepine Versus Oxcarbazepine in Treatment of Trigeminal Neuralgia- a Randomized Controlled Clinical Study

Last checked: Nov 19, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

132

Planned (sponsor's estimate)

Start

Sep 18, 2021

Primary completion

Dec 31, 2021

Study completion Jan 31, 2022

Sponsor

Lead sponsor
Postgraduate Institute of Dental Sciences RohtakAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Trigeminal neuralgia is a neuropathic facial pain condition, characterized by unilateral paroxysmal pain which can be described as stabbing or electric shock like, in the distribution of one or more divisions of trigeminal nerve which is triggered by innocuous stimuli. The attack is provoked by touching or stimulating these trigger zones. There are various pharmacological drugs present for the treatment of trigeminal neuralgia. Carbamazepine and oxcarbazepine are the first-choice drugs for the treatment of TN. Other drugs include lamotrigine , baclofen , gabapentin, antidepressants , eslicarbazepine , sumatriptan \& vixitrigine. The carbamazepine is first choice of drug which has serious side effects including dizziness, memory loss, sleppiness, aplastic anaemia. Oxcarbazepine has similar mechanism of action and found to have lesser adverse events when used in various neuralgias in the place of carbamazepine. But there is still lack of evidence to prove that oxcarbazepine can be used as monotherapy in TN patients.

Conditions

  • Trigeminal Neuralgia

Interventions

  • OxcarbazepineDrug

    oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval

  • CarbamazepineDrug

    carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pain scoresTime frame: 10 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • PGIDS

    Rohtak, Haryana, India · Recruiting

  • Post Graduate Institute of Dental Sciences

    Rohtak, Haryana, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.